Boehringer Ingelheim and Sosei Heptares join forces to develop first-in-class treatments targeting all symptoms of schizophrenia
While ‘positive’ symptoms can be stabilized with antipsychotics, some of which can have side effects, there are currently no approved medicines for ‘negative’ or cognitive symptoms.
- While ‘positive’ symptoms can be stabilized with antipsychotics, some of which can have side effects, there are currently no approved medicines for ‘negative’ or cognitive symptoms.
- The development of a new schizophrenia treatment targeting GPR52 has the potential to address all three aspects of schizophrenia1,2 providing a novel precision treatment.
- “We’re very excited to enter this partnership with Sosei Heptares with this novel approach, which aims to address a huge unmet need of those living with schizophrenia.
- We’re delighted to partner with Boehringer Ingelheim and leverage its leading expertise in neurological disease research and innovation.